Rituximab for Prevention of Acute Graft-Versus Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT).

Trial Profile

Rituximab for Prevention of Acute Graft-Versus Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Rituximab (Primary) ; Antithymocyte globulin; Busulfan; Cyclophosphamide; Cyclophosphamide; Fludarabine; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 Planned End Date changed from 1 Dec 2014 to 1 Mar 2018.
    • 29 Sep 2017 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2017.
    • 20 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top